Divi's Laboratories Overview

  • Founded
  • 1990

Founded
  • Status
  • Public

  • Employees
  • 16,543

Employees
  • Stock Symbol
  • DIVISLAB

Stock Symbol
  • Share Price
  • $41.59

  • (As of Friday Closing)

Divi's Laboratories General Information

Description

Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. Divi operates two segments: the first is Generic APIs and Nutraceuticals, and the second is Custom Synthesis of APIs, intermediates, and specialty ingredients for innovators. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NSE
Primary Office
  • Divi Towers, Cyber Hills
  • Gachibowli
  • Hyderabad, 500032
  • India
+91 040 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Divi's Laboratories Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$41.59 $40.88 $39.48 - $61.12 $10.9B 265M 531K $1.47

Divi's Laboratories Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020
EV 11,710,596 15,157,748 12,841,908 6,921,067
Revenue 1,166,970 1,180,985 921,821 744,706
EBITDA 499,790 526,983 385,052 282,135
Net Income 389,742 397,336 266,706 193,741
Total Assets 1,659,067 1,763,815 1,466,942 1,131,755
Total Debt 405 487 658 5,151
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Divi's Laboratories Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Divi's Laboratories‘s full profile, request access.

Request a free trial

Divi's Laboratories Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated
Drug Discovery
Hyderabad, India
16,543 As of 2022
00.000
000000000 00.000

00000

t esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
000000000000000
Ahmedabad, India
00000 As of 0000
000.00
0000 0000-00-00
00000000 000.00

000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qu
000000000000000
Tokyo, Japan
00000 As of 0000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Divi's Laboratories Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zydus Lifesciences Corporation Ahmedabad, India 00000 000.00 00000000 000.00
00000000 000000 Corporation Tokyo, Japan 00000 00000000
000000000 000000 Corporation Hyderabad, India 00000 00000 000000000 00000
000000000 Corporation Mumbai, India 0000 000000000
00000 000000000000 Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
You’re viewing 5 of 13 competitors. Get the full list »

Divi's Laboratories Patents

Divi's Laboratories Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4079746-A1 Process for the preparation of molnupiravir Pending 23-Apr-2021 0000000000 0
JP-2022167736-A Method for manufacturing molnupiravir Pending 23-Apr-2021 0000000000
US-11407779-B1 Process for the preparation of molnupiravir Active 23-Apr-2021 00000000 0
EP-4036244-A1 Enzymatic process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam Pending 01-Feb-2021 000000000 0
JP-2022117945-A Enzymatic process for preparation of (2s)-2-[(4r)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and conversion to brivaracetam thereof Pending 01-Feb-2021 C12P17/10
To view Divi's Laboratories’s complete patent history, request access »

Divi's Laboratories Executive Team (4)

Name Title Board Seat Contact Info
Satchandra Divi Chief Executive Officer & Board Member
Madhusudana Divi Board Member & Executive
Nilima Divi Board Member & Executive
Murali Divi Ph.D Board Member & Founder
To view Divi's Laboratories’s complete executive team members history, request access »

Divi's Laboratories Board Members (9)

Name Representing Role Since
00000000 0000 Divi's Laboratories Board Member 000 0000
0000000 0000000000 Divi's Laboratories Board Member 000 0000
00000000000 0000 Divi's Laboratories Board Member & Executive 000 0000
000000 0000 00.0 Divi's Laboratories Board Member & Founder 000 0000
000000 0000 Divi's Laboratories Board Member & Executive 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Divi's Laboratories Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Divi's Laboratories Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Divi's Laboratories‘s full profile, request access.

Request a free trial

Divi's Laboratories ESG

Risk Overview

Risk Rating

Updated March, 07, 2022

17.86 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

0.00

Percentile

Laboratory Equipment and Services

Subindustry

00 of 70

Rank

00.0

Percentile

To view Divi's Laboratories’s complete esg history, request access »